Catalyst Pharmaceuticals (CPRX) 8-K Other Events

Exhibit 99.2

Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and

Provides Corporate Update

—Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow

CORAL GABLES, Fla., August 7, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceuticalcompany focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a corporate update.

“This quarter we were pleased to announce the FDA acceptance of our NDA for Firdapse^® for Lambert-Eaton myasthenic syndrome (LEMS) and to receive Priority Review Status for our NDA,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. “With the previous grant of Breakthrough Therapy Designation, the Priority Review underscores the robust potential of Firdapse and the need for a safe and effectiveFDA-approved treatment for LEMS. The recent appointment of our Chief Commercial Officer, Dan Brennan, provides us with extensive commercial experience that will help us build a commercial platform to prepare for a potential launch of Firdapse.”

Q2-18 and Recent Highlights

• FDA Acceptance of NDA and Priority Review Status of Firdapse for LEMS

• Appointed Daniel J. Brennan as Chief Commercial Officer and expanded commercial leadership team with key hires

• Recently added three additional medical science liaisons to the medical affairs team

• Continued progress withpre-commercialization activities for a potential launch of Firdapse

• Ended June 30, 2018 with $73.4 million in cash and investments and no debt

Upcoming Milestones

• Prescription Drug User Fee Act (PDUFA) goal date of November 28, 2018 for Firdapse

• Enroll first patients in SMA Type 3 proof of concept trial in the second half of 2018

• Potential launch of Firdapse for LEMS in early 2019

• Expecttop-line results from Phase 3 CMS(CMS-001) trial in the first half of 2019

• Expecttop-line results from Phase 3 trial forMuSK-MG in the second half of 2019

Financial Results

For the quarter ended June 30, 2018, Catalyst reported a GAAP net loss of $5,965,140, or $0.06 per basic and diluted share, compared to a GAAP net loss of $3,879,901, or $0.05 per basic and diluted share, for the same period in 2017. For the second quarter of 2018,Non-GAAP¹ net loss was the same as GAAP net loss, as there were noNon-GAAP¹ adjustments. In comparison,Non-GAAP¹ net loss for the second quarter of 2017 was $4,090,232 or $0.05 per basic and diluted share, which excludesnon-cash gain of $210,331 attributable to the change in fair value of liability-classified warrants.

For the six months ended June 30, 2018, Catalyst reported a GAAP net loss of $11,665,032, or $0.11 per basic and diluted share, as compared to a GAAP net loss of $8,847,030, or $0.11 per basic and diluted share, for the same period in 2017. For the six months ended June 30, 2018,Non-GAAP¹ net loss was the same as GAAP net loss, as there were noNon-GAAP¹ adjustments. In comparison,Non-GAAP¹net loss for the first six months of 2017 was $8,660,126, or $0.10 per basic and diluted share, which excludesnon-cash loss of $186,904 attributable to the change in fair value of liability-classified warrants.

Research and development expenses for the second quarter of 2018 were $3,704,824 compared to $2,451,751 in the second quarter of 2017. For the six months ended June 30, 2018, research and development expenses were $6,963,866 as compared to $5,265,680 in the same period in 2017. The increase in research and development expenses for the first six months of 2018 was primarily due to increases in consulting expenses as Catalyst prepared to submit its NDA for Firdapse during the first quarter of 2018, milestone expenses in connection with the acceptance of Catalyst’s NDA submission in May 2018, expenses from Catalyst’s medical affairs program, and compensation and related personnel costs, as Catalyst’s expands its headcount to support currently ongoing trials and programs. Catalyst expects that costs related to research and development activities will continue to be substantial throughout 2018 as it continues itson-going clinical studies and Expanded Access Program for Firdapse.

General and administrative expenses for the second quarter of 2018 totaled $2,631,031 as compared to $1,729,520 in the second quarter of 2017. For the six months ended June 30, 2018, general and administrative expenses were $5,305,429 as compared to $3,595,462 in the same period in 2017. The increase when compared to the same period in 2017 is primarily due to increases inpre-commercialization expenses, headcount and corporate expenses as Catalyst builds up its infrastructure and commercial programs in preparation for a potential launch of Firdapse in 2019. Catalyst expects general and administrative expenses, includingpre-commercialization expenses, to continue to increase in 2018 as Catalyst continues to expand its operations in preparation for a potential launch of Firdapse in 2019.

As a development-stage biopharmaceutical company, Catalyst had no revenues in either the second quarter of 2018 and 2017 or the first six months of 2018 and 2017.

¹  Statements made in this press release include anon-GAAP financial measure. Such information is provided as additional information and not as an alternative to Catalyst’s financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP). Thisnon-GAAP financial measure is intended to enhance an overall understanding of Catalyst’s current financial performance. Catalyst believes that thenon-GAAP financial measure presented in this press release provides investors and prospective investors with an alternative method for assessing Catalyst’s operating results in a manner that Catalyst believes is focused on the performance of ongoing operations and provides a more consistent basis for comparison between periods. Thenon-GAAP financial measure in this press release excludes from the calculation of net loss the expense (or the income) associated with the change in fair value of the liability-classifiedwarrants. Non-GAAP net loss per share is calculated by dividingnon-GAAP net loss by the weighted average common shares outstanding.

2

At June 30, 2018, Catalyst had cash and investments of $73.4 million and no debt. Catalyst believes that its existing capital resources will be sufficient to support its planned operations through 2019 (without considering revenues and cash receipts that may be received in 2019 if Catalyst is successful in obtaining an approval of Firdapse and launching the product in 2019, of which there can be no assurance).

More detailed financial information and analysis may be found in Catalyst’s Quarterly Report on Form10-Q, which was filed with the Securities and Exchange Commission (SEC) on August 7, 2018.

Conference Call

Catalyst management will host an investment-community conference call and webcast at 8:30 a.m. ET, tomorrow, Wednesday, August 8, 2018 to discuss the financial results and provide a corporate update. Investors who wish to participate in the conference call may do so by dialing (877)407-8912 for domestic and Canadian callers or (201)689-8059 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the company’s website at www.catalystpharma.com and clicking on the webcast link on the Investors home page. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company’s website at www.catalystpharma.com.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. Firdapse (amifampridine phosphate) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.

Catalyst is also developingCPP-115 to treat refractory infantile spasms.CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril^® (vigabatrin).

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether Firdapse will ever be approved for commercialization, (ii) whether, even if Firdapse is approved for commercialization, Catalyst will be successful in commercializing Firdapse, (iii) whether Catalyst will be the first company to receive an approval for amifampridine(3,4-DAP), giving it5-year marketing exclusivity for its product, and (iv) those other factors described in Catalyst’s Annual Report on Form10-K for the fiscal year 2017 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

3

Investor Contact Brian Korb Solebury Trout (646)378-2923 bkorb@troutgroup.com Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305)420-3200 pmcenany@catalystpharma.com

Media Contact

David Schull

Russo Partners

(212)845-4271

david.schull@russopartnersllc.com

###

4

CATALYST PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2018			2017			2018			2017
Operating costs and expenses:
Research and development	$	3,704,824		$	2,451,751		$	6,963,866		$	5,265,680
General and administrative		2,631,031			1,729,520			5,305,429			3,595,462
Total operating costs and expenses		6,335,855			4,181,271			12,269,295			8,861,142
Loss from operations		(6,335,855	)		(4,181,271	)		(12,269,295	)		(8,861,142	)
Other income, net		370,715			91,039			604,263			201,016
Change in fair value of warrants liability		—			210,331			—			(186,904	)
Loss before income taxes		(5,965,140	)		(3,879,901	)		(11,665,032	)		(8,847,030	)
Provision for income taxes		—			—			—			—
Net loss	$	(5,965,140	)	$	(3,879,901	)	$	(11,665,032	)	$	(8,847,030	)
Net loss per share – basic and diluted	$	(0.06	)	$	(0.05	)	$	(0.11	)	$	(0.11	)
Weighted average shares outstanding – basic and diluted		102,596,446			83,905,827			102,577,005			83,441,650

5

CATALYST PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2018		December 31, 2017
	(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	9,887,939	$	57,496,702
Short-term investments		58,520,956		26,516,711
Prepaid expenses and other current assets		677,341		1,173,744
Total current assets		69,086,236		85,187,157
Investments		5,005,321		—
Property and equipment, net		187,131		191,385
Deposits		8,888		8,888
Total assets	$	74,287,576	$	85,387,430
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	922,593	$	1,945,575
Accrued expenses and other liabilities		2,159,435		2,320,587
Total current liabilities		3,082,028		4,266,162
Accrued expenses and other liabilities,non-current		143,335		157,456
Total liabilities		3,225,363		4,423,618
Total stockholders’ equity		71,062,213		80,963,812
Total liabilities and stockholders’ equity	$	74,287,576	$	85,387,430

6